{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:23:26Z","timestamp":1787383406278,"version":"build-2736575974"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022.06174.PTDC"],"award-info":[{"award-number":["2022.06174.PTDC"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/PRR\/00313\/2025"],"award-info":[{"award-number":["UID\/PRR\/00313\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/00313\/2025"],"award-info":[{"award-number":["UID\/00313\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005727","name":"Universidade de Coimbra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005727","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40291-026-00864-3","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:49:28Z","timestamp":1784119768000},"page":"739-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding and Overcoming Temozolomide Resistance Through CRISPR\/Cas Technologies"],"prefix":"10.1007","volume":"30","author":[{"given":"B\u00e1rbara S.","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-548X","authenticated-orcid":false,"given":"Carla","family":"Vitorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"864_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2024. Available from: https:\/\/gco.iarc.who.int\/today. [Accessed 13 Aug 2025]."},{"key":"864_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/annonc\/mdu050","volume":"25","author":"R Stupp","year":"2014","unstructured":"Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:93\u2013101. https:\/\/doi.org\/10.1093\/annonc\/mdu050.","journal-title":"Ann Oncol"},{"key":"864_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.113983","author":"M Mendes","year":"2024","unstructured":"Mendes M, Nunes S, Cova T, Branco F, Dyrks M, Koksch B, et al. Charge-switchable cell-penetrating peptides for rerouting nanoparticles to glioblastoma treatment. Colloids Surf B Biointerfaces. 2024:1\u201318. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113983.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"16359","DOI":"10.1021\/acsnano.4c01790","volume":"18","author":"F Branco","year":"2024","unstructured":"Branco F, Cunha J, Mendes M, Vitorino C, Sousa JJ. Peptide-hitchhiking for the development of nanosystems in glioblastoma. ACS Nano. 2024;18:16359\u201394. https:\/\/doi.org\/10.1021\/acsnano.4c01790.","journal-title":"ACS Nano"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"864_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma: a comprehensive review. Cancer Drug Resist. 2021;4:17\u201343. https:\/\/doi.org\/10.20517\/cdr.2020.79.","journal-title":"Cancer Drug Resist"},{"key":"864_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/OP.22","volume":"19","author":"R Kotecha","year":"2023","unstructured":"Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key clinical principles in the management of glioblastoma. JCO Oncol Pract. 2023;19:180\u20139. https:\/\/doi.org\/10.1200\/OP.22.","journal-title":"JCO Oncol Pract."},{"key":"864_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05301-9","author":"J White","year":"2024","unstructured":"White J, White MPJ, Wickremesekera A, Peng L, Gray C. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med. 2024:1\u201314. https:\/\/doi.org\/10.1186\/s12967-024-05301-9.","journal-title":"J Transl Med"},{"key":"864_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116588","author":"Q Tang","year":"2024","unstructured":"Tang Q, Ren T, Bai P, Wang X, Zhao L, Zhong R, et al. Novel strategies to overcome chemoresistance in human glioblastoma. Biochem Pharmacol. 2024:1\u201326. https:\/\/doi.org\/10.1016\/j.bcp.2024.116588.","journal-title":"Biochem Pharmacol"},{"key":"864_CR11","unstructured":"The Nobel Prize. The Nobel Prize in chemistry 2020. 2020. Available from: https:\/\/www.nobelprize.org\/prizes\/chemistry\/2020\/popular-information\/ [Accessed 26 May 2024]."},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.1225829","volume":"2012","author":"M Jinek","year":"1979","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 1979;2012:1\u20137. https:\/\/doi.org\/10.1126\/science.1225829.","journal-title":"Science"},{"key":"864_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096. https:\/\/doi.org\/10.1126\/science.1258096.","journal-title":"Science"},{"issue":"46","key":"864_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/2347-8659.2018.58","volume":"5","author":"CJ Yelton","year":"2018","unstructured":"Yelton CJ, Ray SK. Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma. Neuroimmunol Neuroinflamm. 2018;5(46):1\u201318. https:\/\/doi.org\/10.20517\/2347-8659.2018.58.","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"864_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.FREERADBIOMED.2011.10.487","volume":"52","author":"CJ Lin","year":"2012","unstructured":"Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52:377\u201391. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2011.10.487.","journal-title":"Free Radic Biol Med"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.3892\/OL.2016.5261","volume":"12","author":"J Gan","year":"2016","unstructured":"Gan J, Wang F, Mu D, Qu Y, Luo R, Wang Q. RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. Oncol Lett. 2016;12:4515\u201323. https:\/\/doi.org\/10.3892\/OL.2016.5261.","journal-title":"Oncol Lett"},{"key":"864_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FONC.2019.01547","volume":"9","author":"W Yu","year":"2020","unstructured":"Yu W, Zhang L, Wei Q, Shao A. O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2020;9:1\u201311. https:\/\/doi.org\/10.3389\/FONC.2019.01547.","journal-title":"Front Oncol"},{"key":"864_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2023.115726","volume":"215","author":"P Bai","year":"2023","unstructured":"Bai P, Fan T, Wang X, Zhao L, Zhong R, Sun G. Modulating MGMT expression through interfering with cell signaling pathways. Biochem Pharmacol. 2023;215:1\u201318. https:\/\/doi.org\/10.1016\/j.bcp.2023.115726.","journal-title":"Biochem Pharmacol"},{"key":"864_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2025.101139","volume":"62","author":"SR Wu","year":"2025","unstructured":"Wu SR, Sharpe J, Tolliver J, Groth AJ, Chen R, Guerra Garc\u00eda ME, et al. Combining the RCAS\/tv-a retrovirus and CRISPR\/Cas9 gene editing systems to generate primary mouse models of diffuse midline glioma. Neoplasia. 2025;62:1\u201310. https:\/\/doi.org\/10.1016\/j.neo.2025.101139.","journal-title":"Neoplasia"},{"key":"864_CR20","unstructured":"National Center for Biotechnology Information. Temozolomide: compound summary 2025. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/temozolomide [Accessed 17 Aug 2025]."},{"key":"864_CR21","unstructured":"European Medicines Agency. Temodal: summary of product characteristics. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/temodal. [Accessed 17 Aug 2025]."},{"key":"864_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876:1\u201315. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188616.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijpharm.2017.07.056","volume":"531","author":"A Miranda","year":"2017","unstructured":"Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm. 2017;531:372\u201388. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.07.056.","journal-title":"Int J Pharm"},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","volume":"10","author":"W Wick","year":"2014","unstructured":"Wick W, Weller M, Van Den Bent M, Sanson M, Weiler M, Von Deimling A, et al. MGMT testing: the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10:372\u201385. https:\/\/doi.org\/10.1038\/nrneurol.2014.100.","journal-title":"Nat Rev Neurol"},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/nop\/npz039","volume":"7","author":"A Malmstr\u00f6m","year":"2020","unstructured":"Malmstr\u00f6m A, \u0141ysiak M, Kristensen BW, Hovey E, Henriksson R, S\u00f6derkvist P. Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma. Neuro-oncol Pract. 2020;7:68\u201376. https:\/\/doi.org\/10.1093\/nop\/npz039.","journal-title":"Neuro-oncol Pract"},{"issue":"2573","key":"864_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9122573","volume":"9","author":"CRR Rocha","year":"2020","unstructured":"Rocha CRR, Rocha AR, Silva MM, Gomes LR, Latancia MT, Tomaz MA, et al. Revealing temozolomide resistance mechanisms via genome-wide crispr libraries. Cells. 2020;9(2573):1\u201317. https:\/\/doi.org\/10.3390\/cells9122573.","journal-title":"Cells"},{"issue":"289","key":"864_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-025-06261-4","volume":"23","author":"X Li","year":"2025","unstructured":"Li X, Zhang W, Fang Y, Sun T, Chen J, Tian R. Large-scale CRISPRi screens link metabolic stress to glioblastoma chemoresistance. J Transl Med. 2025;23(289):1\u201318. https:\/\/doi.org\/10.1186\/s12967-025-06261-4.","journal-title":"J Transl Med"},{"key":"864_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.20892\/j.issn.2095-3941.2023.0011","volume":"20","author":"J Zhou","year":"2023","unstructured":"Zhou J, Tong F, Zhao J, Cui X, Wang Y, Wang G, et al. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. Cancer Biol Med. 2023;20:385\u2013400. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0011.","journal-title":"Cancer Biol Med"},{"key":"864_CR29","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.7150\/thno.41219","volume":"10","author":"B Han","year":"2020","unstructured":"Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, et al. ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 2020;10:3351\u201365. https:\/\/doi.org\/10.7150\/thno.41219.","journal-title":"Theranostics"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.201901299","volume":"6","author":"Q Wang","year":"2019","unstructured":"Wang Q, Liu X, Zhou J, Yang C, Wang G, Tan Y, et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv Sci. 2019;6:1\u20137. https:\/\/doi.org\/10.1002\/advs.201901299.","journal-title":"Adv Sci"},{"key":"864_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/neuonc\/noad252","volume":"26","author":"F Lang","year":"2024","unstructured":"Lang F, Cornwell JA, Kaur K, Elmogazy O, Zhang W, Zhang M, et al. Abrogation of the G2\/M checkpoint as a chemosensitization approach for alkylating agents. Neuro Oncol. 2024;26:1083\u201396. https:\/\/doi.org\/10.1093\/neuonc\/noad252.","journal-title":"Neuro Oncol"},{"key":"864_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/nn.4620","volume":"20","author":"RD Chow","year":"2017","unstructured":"Chow RD, Guzman CD, Wang G, Schmidt F, Youngblood MW, Ye L, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20:1329\u201341. https:\/\/doi.org\/10.1038\/nn.4620.","journal-title":"Nat Neurosci"},{"issue":"496","key":"864_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4394-6","volume":"18","author":"B Hegge","year":"2018","unstructured":"Hegge B, Sj\u00f8ttem E, Mikkola I. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress. BMC Cancer. 2018;18(496):1\u201319. https:\/\/doi.org\/10.1186\/s12885-018-4394-6.","journal-title":"BMC Cancer"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.7150\/thno.92703","volume":"14","author":"J Zhao","year":"2024","unstructured":"Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang S, et al. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis\/TMZ resistance in the mesenchymal subtype of glioblastoma. Theranostics. 2024;14:2835\u201355. https:\/\/doi.org\/10.7150\/thno.92703.","journal-title":"Theranostics"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/neuonc\/noae059","volume":"26","author":"S Budhiraja","year":"2024","unstructured":"Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S, Saathoff M, et al. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro Oncol. 2024;26:1421\u201337. https:\/\/doi.org\/10.1093\/neuonc\/noae059.","journal-title":"Neuro Oncol"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.celrep.2019.03.047","volume":"27","author":"G MacLeod","year":"2019","unstructured":"MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, et al. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 2019;27:971-86.e9. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.047.","journal-title":"Cell Rep"},{"key":"864_CR37","unstructured":"European Medicines Agency. Lynparza. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza. [Accessed 30 May 2026]."},{"key":"864_CR38","unstructured":"NCT05463848: surgical pembro +\/- olaparib w TMZ for rGBM. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05463848?cond=Glioblastoma&intr=Olaparib&viewType=Card&rank=1\/ [Accessed 30 May 2026]."},{"key":"864_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/1078-0432","volume":"31","author":"F Lang","year":"2025","unstructured":"Lang F, Kaur K, Zaheer J, Ribeiro DL, Yang C. Myt1kKinase: an emerging cell-cycle regulator for cancer therapeutics. Clin Cancer Res. 2025;31:960\u20134. https:\/\/doi.org\/10.1158\/1078-0432.","journal-title":"Clin Cancer Res"},{"key":"864_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110901","author":"K Tomovi\u0107 Pavlovi\u0107","year":"2024","unstructured":"Tomovi\u0107 Pavlovi\u0107 K, Koci\u0107 G, \u0160melcerovi\u0107 A. Myt1 kinase inhibitors: insight into structural features, offering potential frameworks. Chem Biol Interact. 2024:1\u20139. https:\/\/doi.org\/10.1016\/j.cbi.2024.110901.","journal-title":"Chem Biol Interact"},{"key":"864_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9867595","volume":"2020","author":"Y Yang","year":"2020","unstructured":"Yang Y, Tian Z, Guo R, Ren F. Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive cancers by inhibiting Nrf2\/HO-1 and HER2-AKT\/ERK1\/2 pathways. Oxid Med Cell Longev. 2020;2020:1\u201314. https:\/\/doi.org\/10.1155\/2020\/9867595.","journal-title":"Oxid Med Cell Longev"},{"key":"864_CR42","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/MC.22609","volume":"56","author":"B Harder","year":"2017","unstructured":"Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E, et al. Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog. 2017;56:1493\u2013500. https:\/\/doi.org\/10.1002\/MC.22609.","journal-title":"Mol Carcinog"},{"key":"864_CR43","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","volume":"27","author":"JA Quinn","year":"2009","unstructured":"Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.18.8417.","journal-title":"J Clin Oncol"},{"key":"864_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-024-04708-0","volume":"169","author":"Y Yousefi","year":"2024","unstructured":"Yousefi Y, Nejati R, Eslahi A, Alizadeh F, Farrokhi S, Asoodeh A, et al. Enhancing temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). J Neurooncol. 2024;169:129\u201335. https:\/\/doi.org\/10.1007\/s11060-024-04708-0.","journal-title":"J Neurooncol"},{"key":"864_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1342114","author":"R Weber","year":"2024","unstructured":"Weber R, Weller M, Reifenberger G, Vasella F. Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells. Front Oncol. 2024:1\u20137. https:\/\/doi.org\/10.3389\/fonc.2024.1342114.","journal-title":"Front Oncol"},{"key":"864_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2023.100929","volume":"44","author":"X Han","year":"2023","unstructured":"Han X, Abdallah MOE, Breuer P, Stahl F, Bakhit Y, Potthoff AL, et al. Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma. Neoplasia. 2023;44:1\u201310. https:\/\/doi.org\/10.1016\/j.neo.2023.100929.","journal-title":"Neoplasia"},{"key":"864_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11060-023-04531-z","volume":"166","author":"S Zapanta Rinonos","year":"2024","unstructured":"Zapanta Rinonos S, Li T, Pianka ST, Prins TJ, Eldred BSC, Kevan BM, et al. dCas9\/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol. 2024;166:129\u201342. https:\/\/doi.org\/10.1007\/s11060-023-04531-z.","journal-title":"J Neurooncol"},{"key":"864_CR48","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/neuonc\/noaf055","volume":"27","author":"K Lin","year":"2025","unstructured":"Lin K, Zou C, Hubbard A, Sengelmann S, Goudy L, Wang I-C, et al. Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy. Neuro Oncol. 2025;27:1443\u201357. https:\/\/doi.org\/10.1093\/neuonc\/noaf055.","journal-title":"Neuro Oncol"},{"key":"864_CR49","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00f1ez","year":"2021","unstructured":"Nu\u00f1ez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184:2503\u201319. https:\/\/doi.org\/10.1016\/j.cell.2021.03.025.","journal-title":"Cell"},{"key":"864_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26094420","volume":"26","author":"A Seijas","year":"2025","unstructured":"Seijas A, Cora D, Novo M, Al-Soufi W, S\u00e1nchez L, Arana \u00c1J. CRISPR\/Cas9 delivery systems to enhance gene editing efficiency. Int J Mol Sci. 2025;26:4420. https:\/\/doi.org\/10.3390\/IJMS26094420.","journal-title":"Int J Mol Sci"},{"key":"864_CR51","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25:1234\u201357. https:\/\/doi.org\/10.1080\/10717544.2018.1474964.","journal-title":"Drug Deliv"},{"issue":"4","key":"864_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.PREME.2025.100048","volume":"2","author":"J Du","year":"2025","unstructured":"Du J, Wu Q, Liu C, Wang N, Gong C. CRISPR delivery systems for organ-specific targeting: advances and challenges. Precis Med Eng. 2025;2(4):100048. https:\/\/doi.org\/10.1016\/J.PREME.2025.100048.","journal-title":"Precis Med Eng"},{"issue":"10","key":"864_CR53","first-page":"4825","volume":"12","author":"X Yu","year":"2022","unstructured":"Yu X, Zhou Z, Tang S, Zhang K, Peng X, Zhou P, et al. MDK induces temozolomide resistance in glioblastoma by promoting cancer stem-like properties. Am J Cancer Res. 2022;12(10):4825\u201339.","journal-title":"Am J Cancer Res"},{"key":"864_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/CTM2.70359","author":"X Xi","year":"2025","unstructured":"Xi X, Ding X, Wang Q, Liu N, Wang B, Wang G, et al. Targeting the MDK\/c-Myc complex to overcome temozolomide resistance in glioma. Clin Transl Med. 2025:1\u201325. https:\/\/doi.org\/10.1002\/CTM2.70359.","journal-title":"Clin Transl Med"},{"key":"864_CR55","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41565-024-01769-0","volume":"19","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Qin J, Yu D, Liu Y, Song D, Tian K, et al. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. 2024;19:1869\u201379. https:\/\/doi.org\/10.1038\/s41565-024-01769-0.","journal-title":"Nat Nanotechnol"},{"key":"864_CR56","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/2159-8290","volume":"4","author":"S Agnihotri","year":"2014","unstructured":"Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014;4:1198\u2013213. https:\/\/doi.org\/10.1158\/2159-8290.","journal-title":"Cancer Discov"},{"key":"864_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/NCOMMS9904","volume":"6","author":"M Wickstr\u00f6m","year":"2015","unstructured":"Wickstr\u00f6m M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbj\u00f6rnsson B, et al. Wnt\/\u03b2-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun. 2015;6:1\u201310. https:\/\/doi.org\/10.1038\/NCOMMS9904.","journal-title":"Nat Commun"},{"key":"864_CR58","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/S12031-012-9759-8","volume":"47","author":"S Zhang","year":"2012","unstructured":"Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47:346\u201356. https:\/\/doi.org\/10.1007\/S12031-012-9759-8.","journal-title":"J Mol Neurosci"},{"key":"864_CR59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.LFS.2017.08.027","volume":"188","author":"EL Lozada-Delgado","year":"2017","unstructured":"Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mej\u00eda PE. RNA interference for glioblastoma therapy: innovation ladder from the bench to clinical trials. Life Sci. 2017;188:26\u201336. https:\/\/doi.org\/10.1016\/J.LFS.2017.08.027.","journal-title":"Life Sci"},{"key":"864_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ADMA.202501994","volume":"37","author":"F Branco","year":"2025","unstructured":"Branco F, Cunha J, Mendes M, Sousa JJ, Vitorino C. 3D bioprinting models for glioblastoma: from scaffold design to therapeutic application. Adv Mater. 2025;37:1\u201339. https:\/\/doi.org\/10.1002\/ADMA.202501994.","journal-title":"Adv Mater"},{"key":"864_CR61","doi-asserted-by":"publisher","DOI":"10.1017\/ERM.2021.20","author":"P Liu","year":"2021","unstructured":"Liu P, Griffiths S, Veljanoski D, Vaughn-Beaucaire P, Speirs V, Br\u00fcning-Richardson A. Preclinical models of glioblastoma: limitations of current models and the promise of new developments. Expert Rev Mol Med. 2021. https:\/\/doi.org\/10.1017\/ERM.2021.20.","journal-title":"Expert Rev Mol Med"},{"key":"864_CR62","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41596-024-01107-7","volume":"20","author":"A Pagliaro","year":"2025","unstructured":"Pagliaro A, Andreatta F, Finger R, Artegiani B, Hendriks D. Generation of human fetal brain organoids and their CRISPR engineering for brain tumor modeling. Nat Protoc. 2025;20:1846\u201383. https:\/\/doi.org\/10.1038\/s41596-024-01107-7.","journal-title":"Nat Protoc"},{"key":"864_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2022.818696","volume":"15","author":"F Antonica","year":"2022","unstructured":"Antonica F, Aiello G, Soldano A, Abballe L, Miele E, Tiberi L. Modeling brain tumors: a perspective overview of in vivo and organoid models. Front Mol Neurosci. 2022;15:1\u201319. https:\/\/doi.org\/10.3389\/fnmol.2022.818696.","journal-title":"Front Mol Neurosci"},{"key":"864_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15252\/EMMM.201606857","volume":"9","author":"K Kersten","year":"2016","unstructured":"Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2016;9:137:53. https:\/\/doi.org\/10.15252\/EMMM.201606857.","journal-title":"EMBO Mol Med"},{"key":"864_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8391","volume":"6","author":"M Zuckermann","year":"2015","unstructured":"Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K, et al. Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun. 2015;6:1\u20139. https:\/\/doi.org\/10.1038\/ncomms8391.","journal-title":"Nat Commun"},{"key":"864_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16:509\u201320. https:\/\/doi.org\/10.1038\/s41571-019-0177-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"864_CR67","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440\u201355. https:\/\/doi.org\/10.1016\/j.cell.2014.09.014.","journal-title":"Cell"},{"key":"864_CR68","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/NATURE13589","volume":"514","author":"W Xue","year":"2014","unstructured":"Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380\u20135. https:\/\/doi.org\/10.1038\/NATURE13589.","journal-title":"Nature"},{"key":"864_CR69","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1101\/GAD.264861.115","volume":"29","author":"SH Chiou","year":"2015","unstructured":"Chiou SH, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR\/Cas9-mediated somatic genome editing. Genes Dev. 2015;29:1576\u201385. https:\/\/doi.org\/10.1101\/GAD.264861.115.","journal-title":"Genes Dev"},{"key":"864_CR70","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308. https:\/\/doi.org\/10.1038\/nprot.2013.143.","journal-title":"Nat Protoc"},{"key":"864_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2024.114559","volume":"43","author":"MJ Casey","year":"2024","unstructured":"Casey MJ, Chan PP, Li Q, Zu JF, Jette CA, Kohler M, et al. A simple and scalable zebrafish model of Sonic hedgehog medulloblastoma. Cell Rep. 2024;43:1\u201321. https:\/\/doi.org\/10.1016\/j.celrep.2024.114559.","journal-title":"Cell Rep"},{"key":"864_CR72","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1172\/JCI133316","volume":"130","author":"A Hatcher","year":"2020","unstructured":"Hatcher A, Yu K, Meyer J, Aiba I, Deneen B, Noebels JL. Pathogenesis of peritumoral hyperexcitability in an immunocompetent CRISPR-based glioblastoma model. J Clin Invest. 2020;130:2286\u2013300. https:\/\/doi.org\/10.1172\/JCI133316.","journal-title":"J Clin Invest"},{"key":"864_CR73","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.ymthe.2025.01.006","volume":"33","author":"H Zhou","year":"2025","unstructured":"Zhou H, Dai J, Li D, Wang L, Ye M, Hu X, et al. Efficient gene delivery admitted by small metabolites specifically targeting astrocytes in the mouse brain. Mol Ther. 2025;33:1166\u201379. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.006.","journal-title":"Mol Ther"},{"issue":"945","key":"864_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-11418-9","volume":"23","author":"CA Vincent","year":"2023","unstructured":"Vincent CA, Nissen I, Dakhel S, H\u00f6rnblad A, Remeseiro S. Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide. BMC Cancer. 2023;23(945):1\u201314. https:\/\/doi.org\/10.1186\/s12885-023-11418-9.","journal-title":"BMC Cancer"},{"key":"864_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.70097","author":"D Bhatt","year":"2025","unstructured":"Bhatt D, Sundaram RK, L\u00f3pez KSL, Lee T, Gueble SE, Vasquez JC. Development of syngeneic murine glioma models with somatic mismatch repair deficiency to study therapeutic responses to alkylating agents and immunotherapy. Curr Protoc. 2025. https:\/\/doi.org\/10.1002\/cpz1.70097.","journal-title":"Curr Protoc"},{"key":"864_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/S10142-023-01117-W","author":"X Yang","year":"2023","unstructured":"Yang X, Zhang B. A review on CRISPR\/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment. Funct Integr Genom. 2023. https:\/\/doi.org\/10.1007\/S10142-023-01117-W.","journal-title":"Funct Integr Genom"},{"key":"864_CR77","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1038\/s41564-025-02180-8","volume":"10","author":"KS Makarova","year":"2025","unstructured":"Makarova KS, Shmakov SA, Wolf YI, Mutz P, Altae-Tran H, Beisel CL, et al. An updated evolutionary classification of CRISPR-Cas systems including rare variants. Nat Microbiol. 2025;10:3346\u201361. https:\/\/doi.org\/10.1038\/s41564-025-02180-8.","journal-title":"Nat Microbiol"},{"key":"864_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/JCMM.71159","author":"M Aliciaslan","year":"2026","unstructured":"Aliciaslan M, Erbasan E, Erendor F, Sanlioglu S. Advances in CRISPR base editing: from molecular evolution to therapeutic applications in genomic medicine. J Cell Mol Med. 2026:1\u201339. https:\/\/doi.org\/10.1111\/JCMM.71159.","journal-title":"J Cell Mol Med"},{"key":"864_CR79","doi-asserted-by":"publisher","first-page":"79","DOI":"10.12336\/BMT.25.00106","volume":"7","author":"P Vats","year":"2025","unstructured":"Vats P, Baweja B, Saini C, Kushwah AS, Kumar A, Srivastava SK, et al. An overview of CRISPR-artificial intelligence theranostics: current and emerging applications. Biomater Transl. 2025;7:79\u2013120. https:\/\/doi.org\/10.12336\/BMT.25.00106.","journal-title":"Biomater Transl."},{"key":"864_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FPHAR.2025.1552741\/FULL","volume":"16","author":"H Han","year":"2025","unstructured":"Han H, Sun X, Guo X, Wen J, Zhao X, Zhou W. CRISPR\/Cas9 technology in tumor research and drug development application progress and future prospects. Front Pharmacol. 2025;16:1\u201324. https:\/\/doi.org\/10.3389\/FPHAR.2025.1552741\/FULL.","journal-title":"Front Pharmacol"},{"key":"864_CR81","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.tips.2025.02.009","volume":"46","author":"KC Wang","year":"2025","unstructured":"Wang KC, Zheng T, Hubbard BP. CRISPR\/Cas technologies for cancer drug discovery and treatment. Trends Pharmacol Sci. 2025;46:437\u201352. https:\/\/doi.org\/10.1016\/j.tips.2025.02.009.","journal-title":"Trends Pharmacol Sci"},{"key":"864_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/oncotarget.8075","volume":"7","author":"X-Y Mao","year":"2016","unstructured":"Mao X-Y, Dai J-X, Zhou H-H, Liu Z-Q, Jin W-L. Brain tumor modeling using the CRISPR\/Cas9 system: state of the art and view to the future. Oncotarget. 2016;7:1\u201371. https:\/\/doi.org\/10.18632\/oncotarget.8075.","journal-title":"Oncotarget"},{"issue":"4910","key":"864_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21144910","volume":"21","author":"A Ferri","year":"2020","unstructured":"Ferri A, Stagni V, Baril\u00e0 D. Targeting the DNA damage response to overcome cancer drug resistance in hlioblastoma. Int J Mol Sci. 2020;21(4910):1\u201318. https:\/\/doi.org\/10.3390\/IJMS21144910.","journal-title":"Int J Mol Sci"},{"key":"864_CR84","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1021\/ACSAMI.4C15671","volume":"17","author":"Q Li","year":"2025","unstructured":"Li Q, Zhang Z, Wu X, Zhao Y, Liu Y. Cascade-responsive nanoparticles for efficient CRISPR\/Cas9-based glioblastoma gene therapy. ACS Appl Mater Interfaces. 2025;17:4480\u20139. https:\/\/doi.org\/10.1021\/ACSAMI.4C15671.","journal-title":"ACS Appl Mater Interfaces"},{"key":"864_CR85","doi-asserted-by":"publisher","unstructured":"Ciafarone A, Palumbo P, Tai P. The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma. Explor Target Antitumor Ther. 2026;7:1-21. https:\/\/doi.org\/10.37349\/etat.2026.1002374.","DOI":"10.37349\/etat.2026.1002374"},{"key":"864_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-026-00467-8","volume":"7","author":"J-Y Sung","year":"2026","unstructured":"Biomedicine M, Sung J-Y, Hwang K. Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance. Mol Biomed. 2026;7:63. https:\/\/doi.org\/10.1186\/s43556-026-00467-8.","journal-title":"Mol Biomed"},{"key":"864_CR87","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401\u201315. https:\/\/doi.org\/10.1016\/j.csbj.2020.08.031.","journal-title":"Comput Struct Biotechnol J"},{"key":"864_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2015.00055","volume":"5","author":"N Renee Parker","year":"2015","unstructured":"Renee Parker N, Khong P, Fergus Parkinson J, Maarika Howell V, Ruth Wheeler H, Leanne McDonald K, et al. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:1\u20139. https:\/\/doi.org\/10.3389\/fonc.2015.00055.","journal-title":"Front Oncol"},{"key":"864_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2022.818696\/FULL","volume":"15","author":"F Antonica","year":"2022","unstructured":"Antonica F, Aiello G, Soldano A, Abballe L, Miele E, Tiberi L. Modeling brain tumors: a perspective overview of in vivo and organoid models. Front Mol Neurosci. 2022;15:818696. https:\/\/doi.org\/10.3389\/FNMOL.2022.818696\/FULL.","journal-title":"Front Mol Neurosci"},{"key":"864_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells15100876","volume":"15","author":"K K\u00f6pke","year":"2026","unstructured":"K\u00f6pke K, Zuhorn IS, Kruyt FAE. The biomechanics of glioblastoma: why glioblastoma models and clinical reality diverge highlights: what are the main findings? Cells. 2026;15:1\u201324. https:\/\/doi.org\/10.3390\/cells15100876.","journal-title":"Cells"},{"key":"864_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci16050487","volume":"16","author":"NA Sabnis","year":"2026","unstructured":"Sabnis NA, Cooksey LC, Jayakumar H, Mendez MM, Mathew E, Petty RM, et al. Evolving landscape of glioblastoma research: integrating therapeutic advances and diagnostic frontiers. Brain Sci. 2026;16:1\u201346. https:\/\/doi.org\/10.3390\/brainsci16050487.","journal-title":"Brain Sci"},{"key":"864_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS27093842","volume":"27","author":"T Shih","year":"2026","unstructured":"Shih T, Hodeify R, Kaur J, Alnuaimi M, Aboud O. Machine learning-driven metabolomic biomarker discovery in glioblastoma: advances, challenges, and future directions. Int J Mol Sci. 2026;27:1\u201319. https:\/\/doi.org\/10.3390\/IJMS27093842.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"864_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-024-03172-3","volume":"25","author":"G Tanner","year":"2024","unstructured":"Tanner G, Barrow R, Ajaib S, Al-Jabri M, Ahmed N, Pollock S, et al. IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. Genome Biol. 2024;25(24):1\u201329. https:\/\/doi.org\/10.1186\/s13059-024-03172-3.","journal-title":"Genome Biol"},{"key":"864_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2025.105982","volume":"166","author":"Y Dai","year":"2025","unstructured":"Dai Y, Shi C, Zhao K, Tie J, Lian K, Li W, et al. Integrating computational pathology and multi-transcriptomics to characterize glioblastoma heterogeneity and identify prognostic biomarkers. Hum Pathol. 2025;166:1\u201313. https:\/\/doi.org\/10.1016\/j.humpath.2025.105982.","journal-title":"Hum Pathol"},{"issue":"69","key":"864_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-026-01276-6","volume":"10","author":"J Li","year":"2026","unstructured":"Li J, Zhang L, Yu Z, Bao Z, Li D, Wang L. The impact of AI on modern oncology from early detection to personalized cancer treatment. NPJ Precis Oncol. 2026;10(69):1\u201318. https:\/\/doi.org\/10.1038\/s41698-026-01276-6.","journal-title":"NPJ Precis Oncol."},{"key":"864_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gpb.2020.10.005","volume":"19","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genom Proteomics Bioinform. 2021;19:1\u201312. https:\/\/doi.org\/10.1016\/j.gpb.2020.10.005.","journal-title":"Genom Proteomics Bioinform"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00864-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:31:55Z","timestamp":1787380315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00864-3","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors also acknowledge Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT) for funding project 2022.06174.PTDC. The figures were created with BioRender.com.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B\u00e1rbara S. Marques, Maria Mendes, Jos\u00e9 Lu\u00eds Alves, Alberto Pais, and Carla Vitorino have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BSM contributed to conceptualization, methodology, formal analysis, investigation, and writing of the original draft. MM and CV contributed to conceptualization and formal analysis, reviewed and edited the manuscript, and supervised the study. JLA and AP reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}